RETRA

CAS No. 1036069-26-7

RETRA( —— )

Catalog No. M10180 CAS No. 1036069-26-7

RETRA is a small molecule mutant p53 reactivator that activates a set of p53-regulated genes and specifically suppresses mutant p53-bearing tumor cells in vitro and in mouse xenograft.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    RETRA
  • Note
    Research use only, not for human use.
  • Brief Description
    RETRA is a small molecule mutant p53 reactivator that activates a set of p53-regulated genes and specifically suppresses mutant p53-bearing tumor cells in vitro and in mouse xenograft.
  • Description
    RETRA is a small molecule mutant p53 reactivator that activates a set of p53-regulated genes and specifically suppresses mutant p53-bearing tumor cells in vitro and in mouse xenograft; increases in the expression level of p73, releases p73 and poduces tumor-suppressor effects similar to the functional reactivation of p53; a p73 activator.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    MDM2-p53
  • Recptor
    MDM2-p53
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1036069-26-7
  • Formula Weight
    269.333
  • Molecular Formula
    C11H11NO3S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C1CSC(=N1)SCC(=O)C2=CC(=C(C=C2)O)O.Cl
  • Chemical Name
    2-((4,5-dihydrothiazol-2-yl)thio)-1-(3,4-dihydroxyphenyl)ethan-1-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kravchenko JE, et al. Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6302-7. 2. Sonnemann J, et al. Eur J Cancer. 2015 May;51(7):841-51. 3. Santag S, et al. Oncogene. 2013 Aug 8;32(32):3676-85.
molnova catalog
related products
  • MD-224

    MD-224 is a highly potent and efficacious MDM2 degrader based on the proteolysistargeting chimera (PROTAC) concept,and as a new class of anticancer agent.

  • MMRi64

    MMRi64 is a small molecule inhibitor that disrupts Mdm2-MdmX RING-RING interaction interactions in vitro and activates p53 in cancer cells.

  • SAR-405838

    SAR-405838(MI-77301, MI-773) is a potent and highly selective small-molecule inhibitor of MDM2-p53 interaction with Ki of 0.88 nM.